Details of the Drug

General Information of Drug (ID: DM4LECQ)

Drug Name

Vilazodone

Synonyms

Vilazodone [INN]; Vilazodone (TN); 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide; 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Major depressive disorder	6A70.3	Approved	[1], [2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

441.5

Topological Polar Surface Area (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 7 h [3]
Clearance: The clearance of drug is 19.9-25.1 L/h [4]
Elimination: 1% of the dose is recovered unchanged in the urine and 2% of the dose is recovered unchanged in the feces [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 25 hours [4]
Metabolism: The drug is metabolized via the cytochrome P450(CYP)3A4 and also to a minor extent by CYP2C19 and CYP 2D6 [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.03% [7]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 4.85 L/kg [7]

Chemical Identifiers

Formula: C26H27N5O2
IUPAC Name: 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide
Canonical SMILES: C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N
InChI: InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)
InChIKey: SGEGOXDYSFKCPT-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 6918314
ChEBI ID: CHEBI:70707
CAS Number: 163521-12-8
DrugBank ID: DB06684
TTD ID: D0X6BV
VARIDT ID: DR00915
INTEDE ID: DR1687
ACDINA ID: D00728

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Modulator	[2]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[8]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Major depressive disorder

ICD Disease Classification

6A70.3

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
5-HT 1A receptor (HTR1A)	DTT	HTR1A	2.18E-01	-0.11	-0.51
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	6.32E-02	1.30E-01	7.89E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	5.49E-01	5.15E-02	1.92E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	3.40E-01	1.04E-01	7.11E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.43E-01	2.19E-03	1.72E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	3.18E-03	2.30E-01	2.71E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	8.32E-01	4.74E-02	1.73E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Vilazodone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Vilazodone and Vortioxetine.	Depression [6A70-6A7Z]	[51]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Vilazodone and Desvenlafaxine.	Depression [6A70-6A7Z]	[51]
-----------

Coadministration of a Drug Treating the Disease Different from Vilazodone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Vilazodone and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[52]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Vilazodone caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[53]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Vilazodone caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[53]
Oliceridine	DM6MDCF	Moderate	Additive serotonergic effects by the combination of Vilazodone and Oliceridine.	Acute pain [MG31]	[54]
Inotersen	DMJ93CT	Moderate	Increased risk of bleeding by the combination of Vilazodone and Inotersen.	Amyloidosis [5D00]	[55]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Vilazodone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[53]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Vilazodone caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[53]
Tucatinib	DMBESUA	Major	Decreased metabolism of Vilazodone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[53]
Regorafenib	DMHSY1I	Moderate	Increased risk of bleeding by the combination of Vilazodone and Regorafenib.	Colorectal cancer [2B91]	[55]
Ardeparin	DMYRX8B	Moderate	Increased risk of bleeding by the combination of Vilazodone and Ardeparin.	Coronary thrombosis [BA43]	[55]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Vilazodone caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[53]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Vilazodone caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[53]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Vilazodone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[53]
Danaparoid	DM6CLBN	Moderate	Increased risk of bleeding by the combination of Vilazodone and Danaparoid.	Deep vein thrombosis [BD71]	[55]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Vilazodone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[56]
Eslicarbazepine	DMZREFQ	Moderate	Increased risk of hyponatremia by the combination of Vilazodone and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[57]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Vilazodone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[53]
Avapritinib	DMK2GZX	Moderate	Increased risk of bleeding by the combination of Vilazodone and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[55]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Vilazodone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[53]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Vilazodone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Vilazodone and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[58]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Vilazodone caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[53]
Ceritinib	DMB920Z	Major	Decreased metabolism of Vilazodone caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[53]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Vilazodone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[53]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Vilazodone caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[53]
Idelalisib	DM602WT	Major	Decreased metabolism of Vilazodone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[53]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Vilazodone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[53]
Acalabrutinib	DM7GCVW	Moderate	Increased risk of bleeding by the combination of Vilazodone and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[55]
Ibrutinib	DMHZCPO	Moderate	Increased risk of bleeding by the combination of Vilazodone and Ibrutinib.	Mature B-cell lymphoma [2A85]	[55]
Ponatinib	DMYGJQO	Moderate	Increased risk of bleeding by the combination of Vilazodone and Ponatinib.	Mature B-cell lymphoma [2A85]	[55]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Vilazodone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[53]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Vilazodone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[59]
Ozanimod	DMT6AM2	Moderate	Additive serotonergic effects by the combination of Vilazodone and Ozanimod.	Multiple sclerosis [8A40]	[60]
Vorapaxar	DMA16BR	Moderate	Increased risk of bleeding by the combination of Vilazodone and Vorapaxar.	Myocardial infarction [BA41-BA43]	[55]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Vilazodone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[61]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Vilazodone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[62]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Vilazodone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[63]
Choline salicylate	DM8P137	Moderate	Increased risk of bleeding by the combination of Vilazodone and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[55]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Vilazodone caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[53]
Selexipag	DMAHSU0	Moderate	Decreased metabolism of Vilazodone caused by Selexipag mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[64]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Vilazodone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[53]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Vilazodone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[65]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Vilazodone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[66]
LEE011	DMMX75K	Moderate	Decreased metabolism of Vilazodone caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[53]
Plicamycin	DM7C8YV	Moderate	Increased risk of bleeding by the combination of Vilazodone and Plicamycin.	Testicular cancer [2C80]	[55]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Vilazodone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[67]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Vilazodone and Brilinta.	Thrombosis [DB61-GB90]	[55]
Cabozantinib	DMIYDT4	Moderate	Increased risk of bleeding by the combination of Vilazodone and Cabozantinib.	Thyroid cancer [2D10]	[55]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Vilazodone and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[68]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Vilazodone caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[53]
Betrixaban	DM2C4RF	Moderate	Increased risk of bleeding by the combination of Vilazodone and Betrixaban.	Venous thromboembolism [BD72]	[55]
-----------


⏷ Show the Full List of 51 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Vilazodone 10 mg tablet	10 mg	Oral Tablet	Oral
Vilazodone 20 mg tablet	20 mg	Oral Tablet	Oral
Vilazodone 40 mg tablet	40 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7427).
2	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
3	Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD: Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent Sci. 2020 May 27;6(5):672-683. doi: 10.1021/acscentsci.0c00489. Epub 2020 May 4.
4	Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. Clin Drug Investig. 2013 Mar;33(3):199-206. doi: 10.1007/s40261-013-0061-5.
5	Cruz MP: Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
6	Finnen MJ, Herdman ML, Shuster S: Induction of drug metabolising enzymes in the skin by topical steroids. J Steroid Biochem. 1984 May;20(5):1169-73. doi: 10.1016/0022-4731(84)90362-5.
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
9	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
19	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
20	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
21	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
22	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
23	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
24	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
25	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
26	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
27	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
28	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
29	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
30	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
31	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
32	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
33	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
34	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
35	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
36	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
37	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
38	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
39	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
40	Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
41	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
42	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
43	Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
44	Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
45	Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
46	Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
47	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
48	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
49	Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
50	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
51	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
52	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
53	Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
54	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
55	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
56	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
57	Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
58	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
59	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
60	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
61	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
62	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
63	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
64	Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
65	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
66	Cerner Multum, Inc. "Australian Product Information.".
67	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
68	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]